Clinical trials: Cancer of Brain
Respiratory Disease, Cardiovascular Diseases
Hospice Quality Score Assessment Post Pharmacist Intervention
The study aims to investigate the impact of pharmacist delivered interventions on hospice patients quality metric scores.
- Conditions
- Respiratory Disease, Cardiovascular Diseases, Neurologic Disorder, Dementia
- Trial name
- NCT04361669
- Testing
- Medication safety review
- Where
- United States
- Sponsor
- Tabula Rasa HealthCare
Oncology, DIPG
xPedite: A Study to Expedite DIPG and DMG Research
This study will gather data from new and existing patients with patient medical records, and patient/family/caregiver reported information to establish a clear natural history of disease suitable to serve as an external…
- Conditions
- Oncology, DIPG, DMG
- Trial name
- NCT06140719
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- xCures
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
This is a Phase 1/2, open-label first-in-human study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLU-451 monotherapy and BLU-451 in combination with platinum-based chemotherapy (carboplatin…
- Conditions
- Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms, Neoplasms
- Trial name
- NCT05241873
- Testing
- BLU-451, Carboplatin, Pemetrexed
- Where
- 23 sites in United States, Canada and 3 more
- Volunteers
- 103 people
- Sponsor
- Blueprint Medicines Corporation
Brain Edema, TBI (Traumatic Brain Injury)
Dynamic Decompressive Craniotomy
Prospective observational study on patients undergoing decompressive craniotomy
- Conditions
- Brain Edema, TBI (Traumatic Brain Injury), Stroke, Acute, Cerebral Hemorrhage
- Trial name
- NCT05051488
- Testing
- Dynamic craniotomy
- Volunteers
- 20 people
- Sponsor
- Rohit Khanna, MD
Dravet Syndrome, Lennox Gastaut Syndrome
Intermediate-Size Expanded Access Protocol (EAP) for LP352
This is an intermediate-size expanded access program (EAP) study. The purpose of this EAP is to provide continued access to LP352, an investigational drug product being investigated in participants with DEEs.
- Conditions
- Dravet Syndrome, Lennox Gastaut Syndrome, Developmental and Epileptic Encephalopathies
- Trial name
- NCT06149663
- Testing
- LP352
- Where
- 22 sites in United States, Australia
- Sponsor
- Longboard Pharmaceuticals
Glioma, Glioblastoma
ANG1005 in Patients With Recurrent High-Grade Glioma
This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in patients with high-grade glioma. Another purpose of this study is to assess the efficacy, safety, tolerability, and pharmacokinetics…
- Conditions
- Glioma, Glioblastoma, Brain Tumor, Recurrent
- Trial name
- NCT01967810
- Testing
- ANG1005, Bevacizumab
- Where
- 12 sites in United States
- Volunteers
- 73 people
- Sponsor
- Angiochem Inc
Malignant Glioma, Glioblastoma Multiforme
Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma
The experimental anti-cancer drug IL13-PE38QQR, which is being developed for the treatment of malignant brain tumors, is composed of parts of two proteins: the immune system cytokine IL13 and a toxin from the bacterium…
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00064779
- Testing
- IL13-PE38QQR, targeted fusion protein therapy, surgery
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- INSYS Therapeutics Inc
Glioma, Glioblastoma
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
The purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and the maximal tolerated dose (MTD) of VAL-083 in patients with recurrent malignant glioma.
- Conditions
- Glioma, Glioblastoma, Glioblastoma Multiforme, GBM
- Trial name
- NCT01478178
- Testing
- VAL-083 (Dianhydrogalactitol)
- Where
- 5 sites in United States
- Volunteers
- 55 people
- Sponsor
- Kintara Therapeutics, Inc.
Glioblastoma, MGMT-Unmethylated Glioblastoma
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
This Phase I study investigated the side-effects and best dose of microtubule-targeted agent BAL101553 when given together with radiation therapy in treating patients with newly-diagnosed O6-methylguanine-DNA methyltransferase…
- Trial name
- NCT03250299
- Testing
- Microtubule-Targeted Agent BAL101553, Radiation Therapy
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- Basilea Pharmaceutica
Malignant Melanoma, Carcinoma, Non-Small-Cell Lung
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated advanced solid tumor malignancies with…
- Conditions
- Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms
- Trial name
- NCT04543188
- Testing
- PF-07284890, Binimetinib, Midazolam
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 65 people
- Sponsor
- Pfizer
Glioma
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
This study (1438-0003) is open to adults with a tumour in the brain that is positive for the tumour marker delta-like 3 (DLL3). This study is in people with advanced cancer for whom previous treatment was not successful.
- Trial name
- NCT05916313
- Testing
- BI 764532
- Where
- 12 sites in United States, Austria and 4 more
- Volunteers
- 20 people
- Sponsor
- Boehringer Ingelheim
Glioblastoma
A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma
This study is open to adults with newly diagnosed glioblastoma, a type of brain tumor. The study has two parts. Part 1 is open to people who can get their brain tumor removed by surgery.
- Trial name
- NCT05376800
- Testing
- BI 907828 (Brigimadlin)
- Where
- 7 sites in United States, Belgium and 1 more
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
Lennox Gastaut Syndrome, Dravet Syndrome
Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY
This is a prospective, observational study on approximately 70-100 Real World participants affected by LGS, DS, or TSC treated with Epidyolex® as prescribed in the summary of product characteristics.
- Conditions
- Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
- Trial name
- EpiTALY (NCT05485831)
- Testing
- Epidiolex 100 mg/mL Oral Solution
- Where
- 18 sites in Italy
- Volunteers
- 111 people
- Sponsor
- Jazz Pharmaceuticals
ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC)
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
IDE574 is a synthetically manufactured small molecule inhibitor that co-targets the lysine acetyltransferase enzymes KAT6 and KAT7.
- Conditions
- ER+, HER 2- Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC), Microsatellite Stable (MSS) Colorectal Carcinoma
- Trial name
- NCT07540572
- Testing
- IDE574, Fulvestrant injection
- Where
- 11 sites in United States
- Volunteers
- 160 people
- Sponsor
- IDEAYA Biosciences
Advanced Cancer
DM-CHOC-PEN Plus Radiation for Brain Tumors
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) is a polychlorinated pyridyl cholesterol carbonate that is lipophilic, electrically neural, crosses the blood brain barrier (BBB), ability to localize in intracranial…
- Trial name
- NCT03371004
- Testing
- 4-Demethyl-4-cholesteryloxycarbonylpenclomedine
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- DEKK-TEC, Inc.
Brain Edema, Brain Tumor
Tolerability Study of Xerecept® in Pediatric Patients
This study is being conducted to evaluate the safety and tolerability of Xerecept® in children with central nervous system tumors and to identify appropriate doses of Xerecept® to be used in subsequent pediatric clinical trials.
- Trial name
- NCT01369121
- Testing
- XERECEPT
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Celtic Pharma Development Services
Brain Cancer, Brain Neoplasm
Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects
Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies.
- Conditions
- Brain Cancer, Brain Neoplasm, Glioma, Glioblastoma
- Trial name
- CAPTIVE (NCT02798406)
- Testing
- DNX-2401, pembrolizumab
- Where
- 15 sites in United States, Canada
- Volunteers
- 49 people
- Sponsor
- DNAtrix, Inc.
Brain Injuries, Subarachnoid Hemorrhage
An Evaluation of a Non-invasive Brain Monitor
HS-1000 device, a proprietary new non-invasive brain monitor, is expected to safely and accurately monitor physiological signs of the brain with minimal discomfort to patients, providing information about normal or abnormal…
- Conditions
- Brain Injuries, Subarachnoid Hemorrhage, Vasospasm, Intracranial, Hydrocephalus
- Trial name
- NCT02775136
- Testing
- HS-1000 recording
- Where
- 4 sites in Germany
- Volunteers
- 160 people
- Sponsor
- HeadSense Medical
Glioblastoma, Recurrent Glioblastoma
Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
This is a multicenter, Phase 2 study to assess the activity of tesevatinib in patients with recurrent glioblastoma.
- Conditions
- Glioblastoma, Recurrent Glioblastoma, Brain Tumor
- Trial name
- NCT02844439
- Testing
- Tesevatinib
- Where
- 11 sites in United States
- Volunteers
- 40 people
- Sponsor
- Kadmon Corporation, LLC